



**Michigan Medicine Laboratories**

1500 East Medical Center Drive  
Ann Arbor, MI 48109  
(800) 862-7284 (734) 936-2598

---

**ANATOMIC PATHOLOGY CONSULTATION REPORT**

---

<b>Order Number:</b>	<b>OC-20-8265</b>	<b>Referred by:</b>
<b>First Name:</b>	JULIE	DR. BAKER
<b>Last Name:</b>	RITA	GENERAL HOSPITAL
<b>MRN:</b>	12456789	123 MAIN ST
<b>Gender:</b>	Female <b>Age:</b> 72 Y <b>DOB:</b> 11/1/1947	ANYWHERE, MI 48001
<b>Date Received:</b>	04/10/2020	
<b>Date Completed:</b>	04/11/2020	

---

**DIAGNOSIS:**

Endometrium, biopsy (20-JS-00635, A1-A2; 4/3/2020): High-grade sarcomatoid malignant neoplasm. See comment.

---

Dear Dr. Baker,

Thank you for sharing this case with our Gynecologic Pathology Consultation Service. You have requested our opinion on the endometrial biopsy from Julie Smith a 72 year old woman with a history of marked anemia and vaginal bleeding as well as a firm and distended abdomen associated with numerous abdominal wall lesions.

Sections from the endometrial biopsy show fragments of a high-grade malignant neoplasm composed of spindle cells with high nuclear to cytoplasmic ratio and mild-to-moderate nuclear pleomorphism. Occasional cells have eccentrically placed nuclei. While some fragments appear discohesive, others show solid or corded growth with myxoid stroma. Rare tumor fragments show a suggestion of vague fascicular architecture. There are areas of necrosis, and mitotic figures are easily identified (at least 13 mitotic figures per 10 high-power fields). An entrapped benign gland is noted, without obvious periglandular condensation. An overt carcinomatous component is not seen. The provided immunohistochemical stains demonstrate that the neoplastic cells are positive for PAX8 (patchy), CD10 (patchy), muscle specific actin (patchy), cyclin D1, smooth muscle actin (focal), and p16, and negative for pancytokeratin, EMA, CAM5.2, WT1, GATA3, estrogen receptor, synaptophysin, and chromogranin. The neoplastic cells show increased but not definitively aberrant p53 protein expression. An immunohistochemical stain for desmin performed here is negative.

Overall, the morphologic and immunophenotypic features are those of a high-grade malignant neoplasm, lacking specific differentiation based on the currently available material. This may represent the sarcomatous component of a carcinosarcoma, high-grade endometrial stromal sarcoma, or an undifferentiated uterine sarcoma. Classification of this neoplasm should be more straightforward based on the resection specimen that is likely to be forthcoming. Follow-up is greatly appreciated.

Again, thank you for the opportunity to participate in the care of this patient. Your materials will be returned to you. Please do not hesitate to contact me at 734-123-1234 if you have any questions or concerns regarding the above

---

**First Name:** JULIE  
**Last Name:** SMITH  
**Order Number:** OC-20-8265

**Clinic:** ABCD

diagnosis.

Sincerely,



Stephanie Skala, M.D.

House Officer(s):

ABUBAKER ELSHAIKH

**Materials Received:**

<b>A</b>	<b>Outside Case Number:</b>	<b>20-JS-00635</b>
	Materials Received:	Number of prepared slides: 21 Number of unstained slides: 0 Number of blocks: 1

**CPT Codes:**

Specimen	CPT Code	Number of Charges
A	88321	1
A	88342	1

**Laboratory Accrediting Agency Compliance Statement:**

If immunostain testing was performed on this case, the testing was developed and the performance characteristics were determined by the University of Michigan Clinical Immunoperoxidase Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. (The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.) Appropriate negative and positive controls were run and demonstrated expected results. Most antibodies (including ER, PR, and HER2/neu) were not validated on decalcified tissues; negative staining on decalcified specimens should therefore be viewed with discretion, as a falsely negative result cannot be excluded. The Coreo ACIS instrument (if used for any test on this case) is FDA approved.

Performing site:

NCRC  
NCRC Department of Pathology and Clinical Laboratories  
2800 Plymouth Rd., Building 35  
Ann Arbor, MI 48109

CLIA Director: Riccardo Valdez, MD

CLIA Number: 23D1088637

**First Name:** JULIE  
**Last Name:** SMITH  
**Order Number:** OC-20-8265

**Clinic:** ABCD